Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

5(62.5%)

N/A

3(37.5%)

8Total

Phase 4(5)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03599739Completed

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

Role: lead

NCT05012189Phase 4Unknown

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Role: lead

NCT03965195Phase 4Unknown

Recombinant Influenza Vaccination in U.S. Nursing Homes

Role: lead

NCT02882100Phase 4Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Role: lead

NCT04732819Not ApplicableCompleted

Improving COVID-19 Vaccine Uptake in Nursing Homes

Role: collaborator

NCT02933723Not ApplicableUnknown

Immunogenicity of Influenza Vaccine in Long Term Care

Role: lead

NCT03209570Not ApplicableCompleted

A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting

Role: lead

NCT01815268Phase 4Unknown

High-Dose Influenza Vaccine in Nursing Homes

Role: lead

NCT01720277Phase 4Completed

High Dose Influenza Vaccine in Nursing Home - Pilot Study

Role: lead

All 9 trials loaded